# Anthony Elias

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/anthony-elias/

## Facts

| Field | Value |
| --- | --- |
| Citations | 24,748 |
| Field | Advanced Breast Cancer Therapies |
| h-index | 72 |
| i10-index | 190 |
| Last Known Institution | Cancer Research Center |
| OpenAlex ID | https://openalex.org/A5091848952 |
| ORCID iD | https://orcid.org/0000-0002-6509-9211 |
| Works | 492 |

## Researcher papers

- [Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/breast-cancer-version-3-2020-nccn-clinical-practice-guidelines-in-oncology/)
- [Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/breast-cancer-version-3-2022-nccn-clinical-practice-guidelines-in-oncology/)
- [Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer](https://scholariq.org/papers/effect-of-pembrolizumab-plus-neoadjuvant-chemotherapy-on-pathologic-complete/)
- [Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/breast-cancer-version-3-2024-nccn-clinical-practice-guidelines-in-oncology/)
- [Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas](https://scholariq.org/papers/phase-ii-study-of-sorafenib-in-patients-with-metastatic-or-recurrent-sarcomas/)
- [Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer](https://scholariq.org/papers/adaptive-randomization-of-veliparib-carboplatin-treatment-in-breast-cancer/)
- [Adaptive Randomization of Neratinib in Early Breast Cancer](https://scholariq.org/papers/adaptive-randomization-of-neratinib-in-early-breast-cancer/)
- [NCCN Guidelines® Insights: Breast Cancer, Version 4.2023](https://scholariq.org/papers/nccn-guidelines-insights-breast-cancer-version-4-2023/)
- [w4200350191](https://scholariq.org/papers/w4200350191/)
- [Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial](https://scholariq.org/papers/durvalumab-with-olaparib-and-paclitaxel-for-high-risk-her2-negative-stage-ii-iii/)
- [Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer](https://scholariq.org/papers/association-of-event-free-and-distant-recurrence-free-survival-with-individual/)
- [Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2.](https://scholariq.org/papers/pembrolizumab-plus-standard-neoadjuvant-therapy-for-high-risk-breast-cancer-bc/)

## Researcher topics

- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Estrogen and related hormone effects](https://scholariq.org/topics/estrogen-and-related-hormone-effects/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Sarcoma Diagnosis and Treatment](https://scholariq.org/topics/sarcoma-diagnosis-and-treatment/)

## Researcher university

- [Cancer Research Center](https://scholariq.org/institutions/cancer-research-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.